What is Sino Biopharmaceutical Cash Flow from Financing?
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
six
months ended in Jun. 2024,
Sino Biopharmaceutical paid$50 Mil more to buy back shares than it received from issuing new shares.
It spent$370 Mil paying down its debt.
It paid$0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It received$0 Mil from paying cash dividends to shareholders.
It spent$145 Mil on other financial activities.
In all, Sino Biopharmaceuticalspent$565 Mil on financial activities for the
six
months ended in Jun. 2024.
Sino Biopharmaceutical Cash Flow from Financing Historical Data
The historical data trend for Sino Biopharmaceutical's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Sino Biopharmaceutical Cash Flow from Financing Chart
Sino Biopharmaceutical Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Sino Biopharmaceutical's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-916 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sino Biopharmaceutical (OTCPK:SBMFF) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Sino Biopharmaceutical's issuance of stock for the
six
months ended in Jun. 2024 was $0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Sino Biopharmaceutical's repurchase of stock for the
six
months ended in Jun. 2024 was $-50 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Sino Biopharmaceutical's net issuance of debt for the
six
months ended in Jun. 2024 was $-370 Mil.
Sino Biopharmaceutical spent$370 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Sino Biopharmaceutical's net issuance of preferred for the
six
months ended in Jun. 2024 was $0 Mil.
Sino Biopharmaceutical paid$0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Sino Biopharmaceutical's cash flow for dividends for the
six
months ended in Jun. 2024 was $0 Mil.
Sino Biopharmaceutical received$0 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Sino Biopharmaceutical's other financing for the
six
months ended in Jun. 2024 was $-145 Mil.
Sino Biopharmaceutical spent$145 Mil on other financial activities.
Sino Biopharmaceutical Cash Flow from Financing Related Terms
Thank you for viewing the detailed overview of Sino Biopharmaceutical's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.
Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SBMFF has been successfully added to your 